Haisco Pharmaceutical Group Co.,Ltd

The company is a specialized pharmaceutical group listed company focusing on research and development of new drugs, integrating manufacturing, sales and promotion. The company's R&D focuses on diseases such as perioperative period, tumors, immunity, diabetes and complications. Currently, it has established a series of independent intellectual property drug pipelines, and several innovative drug projects are in the clinical trial stage. The company is a diversified and specialized pharmaceutical group integrating R&D, manufacturing, promotion and marketing of new drugs. The company's main products include the innovative drug cicpofol injection, dolasetron mesylate injection, polyene phosphatidylcholine injection, haloperthione melitracine tablets, and methylprednisolone sodium succinate for injection. Corporate honors: It won the first prize of the Sichuan Science and Technology Progress Award in 2019 and 2022, and the third prize of the Liaoning Science and Technology Progress Award in 2021; the company's self-developed product, cyclopophenol, is the first Class 1 innovative intravenous anesthetic drug with independent intellectual property rights in China, and won the special new product of Liaoning Province in 2022; HSK7653, a Class 1 novel drug developed independently by the company, won the second prize in the “China (Xiaoshan) Biomedical Industry High-Value Patent Cultivation Competition” in 2023.